Bio-Rad Laboratories, Inc.
BIOHealthcareNASDAQMedical Devices · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 28
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. The $8.52B market capitalization puts BIO squarely in mid-cap range for its industry. It operates through two segments, Life Science and Clinical Diagnostics.
Market Cap
$8.52B
Beta
1.06
P/E (TTM)
52.95
P/E (Fwd)
32.73
EPS (TTM)
$6.01
EPS (Fwd)
$9.72
ROE
2.5%
ROA
1.8%
Cash
$1.56B
Total Debt
$1.38B
Free CF
$229.8M
52W Change
40.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.56B in cash comfortably exceeding the $1.38B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $229.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 2.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.8% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.80B (2022) to $2.58B (2025).
At over 50x earnings, BIO carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bio-Rad Laboratories, Inc. and its sector.